About GileadCopy link to section
What is Gilead?Copy link to section
Gilead Sciences is a biopharmaceutical company specialising in various therapies for several diseases. Founded in 1987 and headquartered in Foster City, California, Gilead is best known for its research, development, and commercialisation of medicines for diseases including HIV/AIDS, viral hepatitis, cancer, and inflammatory diseases.
How does Gilead make money?Copy link to section
It makes money by selling pharmaceutical products. This includes medicines and other therapies. It has four main therapeutic areas, including HIV/AIDS, liver diseases, oncology, and respiratory diseases.
It also generates revenue from licensing agreements and partnerships with other companies in the biopharma industry. Gilead also has a pipeline of drugs in the development stage, which can potentially add to its revenue if approved.
What is Gilead’s best selling product?Copy link to section
Its best selling product is Biktarvy, which is a daily tablet for the treatment of HIV-1 infection. In quarter 4 of 2022, Biktarvy generated $1.95 billion in net product sales, a 9% increase from the previous year. Biktarvy is the most prescribed HIV regimen in the United States.
The company also has a range of other top-selling therapies, including Truvada (for HIV), Veklury (for COVID-19), and Yescarta (for cancer treatment.
Who are the key executives at Gilead?Copy link to section
Daniel O’Day is Gilead’s currency chairman and chief executive officer. Here are some other members of its executive team.
- Daniel P. O’Day. Chairman & CEO
- Andrew D. Dickinson. Exec. VP & CFO
- Deborah H. Telman. Exec. VP of Corp. Affairs, Gen. Counsel & Corp.
- Johanna Mercier. Chief Commercial Officer
- Merdad V. Parsey M.D., Ph.D. Chief Medical Officer
- Sandra Patterson. Sr. VP, Corp. Controller & Principal Accounting Officer
- Jacquie Ross C.F.A.. VP of Investor Relations
- Jyoti K. Mehra Exec. VP of HR
- Michael Quigley Ph.D. Sr. VP of Research Biology
- Linda Slanec Higgins Ph.D. Sr. VP & Head of External Innovation
Where can I buy shares in Gilead?Copy link to section
You can buy Gilead stock on a stock trading platform. These platforms are extremely simple to use but there are different options to suit your specific needs. If you are a first-time investor you might want to use a trading platform for beginners, while if you plan on doing a lot of trading from your phone, a stock trading app might be best.
Are there any other ways to invest in Gilead?Copy link to section
The simplest way to invest in Gilead is to buy shares through a stock broker. However, you can also invest through an ETF or a fund. The best ETFs allow you to invest in the stock market more generally rather than focus on one company.
More about the GILD priceCopy link to section
What is the Gilead stock price today?Copy link to section
The GILD stock price today is currently $80.36 as of 27 March, 2023. The price of Gilead is up 35.24% over the past 52 weeks. You can use the live Gilead stock chart to track the NASDAQ:GILD price in real time above, or compare the Gilead value today to its past performance using the Gilead financials tab at the top of this page.
What is the 52-week low for Gilead stock?Copy link to section
The 52-week low for Gilead stock is $57.17. GILD stock is currently 40.91% above the 52-week low.
What is the 52-week high for Gilead stock?Copy link to section
The 52-week high for Gilead stock is $98.74. GILD stock is currently 10.24%below the 52-week high.
What is the stock forecast for Gilead?Copy link to section
The average Gilead stock forecast has a price target of $90.15 by the end of 2023. Gilead’s latest financial results, the broader economic outlook, and the amount of competition in the industry all influence these forecasts.
It’s best to take analyst forecasts with a grain of salt but you can use their estimates to help you understand the weight of opinion about a stock.
More stock guidesCopy link to section
FAQsCopy link to section
Gilead’s market capitalisation is $100.35 billion. This is calculated by multiplying the number of shares that have been issued by the current GILD share price. Another way of measuring this is enterprise value, which includes Gilead’s debt obligations. Gilead’s enterprise value is $115.25 billion.
It went public in January 1992 via an initial public offering. Its IPO raised $86.25 million.
The largest holder of GILD stock is BlackRock, which owns 10.53% of the company.
The pharmaceutical industry is competitive and includes some of the largest companies in the world. Here’s a look at a few of Gilead’s biggest competitors.
- Pfizer. Pfizer is an American pharmaceutical company and known for its Covid vaccine.
- Novartis. Novartis is based in Switzerland and is one of the largest pharma companies
- Teva Pharmaceuticals. Teva is an Israeli pharmaceutical company.
Yes, Gilead has split its stock 5 times. The most recent was in 2013. Every split has been a 2-for-1.
Gilead reports earnings four times per year at the end of each quarter. The exact dates can vary and it is recommended that you visit the Gilead investor relations page for the most up-to-date information. It generally reports in March, June, September, and December.
Yes, Gilead is a dividend-paying stock and has a current yield of 3.81%.
Invezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >